Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 470

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 470
---
 Committee of Sponsoring Organizations (COSO) of the Treadway Commission. Based
on the criteria established by COSO management concluded that the Company’s internal control over financial reporting was effective
as of December 31, 2024.

This Report does not include
an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting
as smaller reporting companies are not required to include such report and emerging growth companies (“EGC’s”) are exempt
from this requirement entirely until they are no longer an EGC. Management’s report is not subject to attestation by the Company’s
independent registered public accounting firm.

Changes
in Internal Control over Financial Reporting

There were no additional changes in our internal control over financial reporting (as defined in Rule
13(a)-15(f) of the Exchange Act) that occurred during the period covered by this annual report that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.

Item
9B. Other Information.

None.

Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not
applicable.

PART
III

Item
10. Directors, Executive Officers and Corporate Governance.

Our
directors and executive officers and their ages as of the date of this Report are as follows:

    Name

    Age
     
    Position
  
    Erez
    Aminov
     
    47
     
    Chief
    Executive Officer and Chairman
  
    Michelle
    Yanez, MBA
     
    53
     
    Chief
    Financial Officer, Treasurer, and Secretary
  
    Matthew
    Pratt Whalen, CPA
     
    45
     
    Director
  
    Matthew
    Paul Del Giudice, M.D.
     
    43
     
    Director
  
    Craig
    Eagle, M.D.
     
    57
     
    Director
  
    Edward
    MacPherson
     
    36
     
    Director

The
following is a brief biography of each of our current executive officers and directors:

55

Executive
Officers and Directors

Erez
Aminov has served as our Chief Executive Officer and Chairman since August 2024. Mr. Aminov is an experienced biotechnology consultant
and is also the Chief Executive Officer of MIRA Pharmaceuticals Inc. (“MIRA”). Mr. Aminov’s experience in the biotech
consulting sector